Although new techniques (i.e., droplet digital-PCR, next-generation sequencing, advanced flow cytometry) are being developed, DNA-based allele-specific real-time quantitative (RQ)-PCR is still the gold standard for sensitive and accurate immunoglobulin/T cell receptor (IG/TR)-based minimal residual disease (MRD) monitoring, allowing the detection of up to 1 leukemic cell in 100,000 normal lymphoid cells. We herewith describe the standard PCR procedure which has been developed and standardized (with minor modification in single labs) through the last 20 years of activity of the EuroMRD Consortium, a volunteer activity of expert laboratories that is continuously providing education, standardization, quality control rounds, and guidelines for interpretation of RQ-PCR data.

Cazzaniga, G., Songia, S., Biondi, A. (2021). Pcr technology to identify minimal residual disease. In C. Cobaleda, I. Sánchez-García (a cura di), Leukemia Stem Cells : Methods and Protocols (pp. 77-94). New York : Humana Press Inc. [10.1007/978-1-0716-0810-4_6].

Pcr technology to identify minimal residual disease

Cazzaniga G.
;
Biondi A.
2021

Abstract

Although new techniques (i.e., droplet digital-PCR, next-generation sequencing, advanced flow cytometry) are being developed, DNA-based allele-specific real-time quantitative (RQ)-PCR is still the gold standard for sensitive and accurate immunoglobulin/T cell receptor (IG/TR)-based minimal residual disease (MRD) monitoring, allowing the detection of up to 1 leukemic cell in 100,000 normal lymphoid cells. We herewith describe the standard PCR procedure which has been developed and standardized (with minor modification in single labs) through the last 20 years of activity of the EuroMRD Consortium, a volunteer activity of expert laboratories that is continuously providing education, standardization, quality control rounds, and guidelines for interpretation of RQ-PCR data.
Capitolo o saggio
Immunoglobulin; Minimal residual disease; Rearrangement; RQ-PCR; T cell receptor;
Immunoglobulin; Minimal residual disease; Rearrangement; RQ-PCR; T cell receptor; Humans; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Real-Time Polymerase Chain Reaction; Receptors, Antigen, B-Cell; Receptors, Antigen, T-Cell
English
Leukemia Stem Cells : Methods and Protocols
Cobaleda, C; Sánchez-García, I
10-nov-2020
2021
978-1-0716-0809-8
2185
Humana Press Inc.
77
94
Cazzaniga, G., Songia, S., Biondi, A. (2021). Pcr technology to identify minimal residual disease. In C. Cobaleda, I. Sánchez-García (a cura di), Leukemia Stem Cells : Methods and Protocols (pp. 77-94). New York : Humana Press Inc. [10.1007/978-1-0716-0810-4_6].
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/336820
Citazioni
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
Social impact